Tuesday, May 24, 2016

BRIEF-Thunderbolt Pharma acquires rights to Dual Antagonist program from Astellas

* Thunderbolt Inc acquired all rights to Astellas BAFF/APRIL

Dual Antagonist program through an asset purchase agreement

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)